Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer

Item
http://www.wikidata.org/entity/Q28282078
Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysisRole of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patientsA phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.Metabolism considerations for kinase inhibitors in cancer treatmentBowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.A phase I/II trial of vandetanib for patients with recurrent malignant glioma.Epidermal growth factor receptor inhibition and non-small cell lung cancer.Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patientsLapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.Long-term disease stabilization following treatment with erlotinib in heavily pretreated patients with wild-type epidermal growth factor receptor non-small-cell lung carcinoma: Two case reports.HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinibHigh PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma.Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects.
P2860

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer

Item
http://www.wikidata.org/entity/Q28282078
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Skin rash and bronchoalveolar ...... tic non-small cell lung cancer
@ast
Skin rash and bronchoalveolar ...... tic non-small cell lung cancer
@en
Skin rash and bronchoalveolar ...... tic non-small cell lung cancer
@nl
type
label
Skin rash and bronchoalveolar ...... tic non-small cell lung cancer
@ast
Skin rash and bronchoalveolar ...... tic non-small cell lung cancer
@en
Skin rash and bronchoalveolar ...... tic non-small cell lung cancer
@nl
prefLabel
Skin rash and bronchoalveolar ...... tic non-small cell lung cancer
@ast
Skin rash and bronchoalveolar ...... tic non-small cell lung cancer
@en
Skin rash and bronchoalveolar ...... tic non-small cell lung cancer
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Skin rash and bronchoalveolar ...... tic non-small cell lung cancer
@en
P2093
P304
P31
P356
10.1016/J.LUNGCAN.2005.09.002
P407
P433
P478
P577
P698